Last reviewed · How we verify
NCT06981546: MOGADOR
Modeling Clinical Outcomes in Gambling Addiction
trial in Gambling Disorder in 268 participants. Not yet recruiting.
1 September 2029
Quick facts
| Lead sponsor | Hospices Civils de Lyon |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 268 |
| Start date | 1 September 2025 |
| Primary completion | 1 September 2029 |
| Estimated completion | 1 September 2030 |
| Sites | 9 locations across France |
Conditions studied
- Gambling Disorder — all drugs for Gambling Disorder →
Sponsor
Hospices Civils de Lyon — full company profile →
Who can join
18 and older, any sex, with Gambling Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Gambling disorder (GD) is recognized as an addictive disorder. Financial consequences of GD are often dramatic, inducing professional, familial, legal and medical repercussions and particularly mental health consequences. MOGADOR is a longitudinal, multicentric, prospective, prognostic study, which aims to identify factors predicting the evolution of french patients with GD in care centers particularly involved in the management of GD. The main goal will focus on evolution of DSM-5 (Diagnostic and Statistical Manual of Mental Disorder 5th edition) GD criteria during the first year of follow-up. The prognostic factors will be collected at base-line and they will be considered to influence the long-term prognosis of patients. For patients suffering of GD, our main hypothesis is that initial factors like individual socio-demographic characteristics, clinical psychiatric profiles, addiction comorbidities, and behaviour are associated with the clinical prognosis (total remission of DSM-5 criteria of GD at 12 months). MOGADOR will be the first study, aiming to model prognostic aspects of GB in populations specially monitored for this disorder.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06981546
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gambling Disorder
Currently open trials in the same condition.
- NCT03669315 — Modulating Inhibitory Control Networks in Gambling Disorder With Theta Burst Stimulation · Phase 3 · recruiting
Other Hospices Civils de Lyon trials
Trials by the same sponsor.
- NCT07569536 — Efficacy of the Alpha 2 Agonist Dexmedetomidine for Sympathetic Deactivation in REfractory Septic Shock · Phase 3 · not yet recruiting
- NCT07529314 — Evaluating Interventional Radiology for Cancer Pain Management · NA · not yet recruiting
- NCT07273929 — Comparative Study of the Effectiveness of Three Access Routes for Implanting an Electronic Intracardiac Device · Phase 3 · not yet recruiting
- NCT07474532 — Attitudes and Beliefs Related to Benzodiazepine Deprescribing · not yet recruiting
- NCT07313007 — Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06981546 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospices Civils de Lyon
- Last refreshed: 20 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06981546.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing